Search

Nimbex賽機寧

Nimbex

cisatracurium

Manufacturer:

Aspen Pharmacare Asia

Distributor:

Cordial Trading
/
Primal
Concise Prescribing Info
Contents
Cisatracurium besylate
Indications/Uses
Neuromuscular-blocking agent for use during surgical & other procedures in adult & childn ≥1 mth. For use in adult requiring intensive care. Adjunct to general anaesth or sedation in the ICU to relax skeletal muscles & to facilitate tracheal intubation & mechanical ventilation.
Click to view Nimbex detailed prescribing information
Dosage/Direction for Use
IV bolus inj Adult Tracheal intubation: 0.15 mg/kg. Maintenance: 0.03 mg/kg. Childn 1 mth to 12 yr Tracheal intubation: 0.15 mg/kg administered rapidly over 5-10 sec. Maintenance: 0.02 mg/kg (2-12 yr). IV infusion Adult & childn 2-12 yr Initial infusion rate: 3 mcg/kg/min. After an initial period of stabilisation, rate of 1-2 mcg/kg/min should be adequate to maintain block.
Click to view Nimbex detailed prescribing information
Overdosage
View Nimbex overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to cisatracurium, atracurium or benzenesulfonic acid.
Click to view Nimbex detailed prescribing information
Special Precautions
Hypersensitivity to other neuromuscular blocking agents. Patients w/ myasthenia gravis & other forms of neuromuscular diseases; severe acid-base &/or serum electrolyte abnormalities; history of malignant hyperthermia; undergoing surgery w/ induced hypothermia; burns. ICU patients. Neonates <1 mth. Do not apply into the infusion line of a blood transfusion. Should not be used during pregnancy. Lactation.
Click to view Nimbex detailed prescribing information
Adverse Reactions
Commonly bradycardia, hypotension. Uncommonly cutaneous flushing, bronchospasm, rash & very rarely anaphylactic reaction, myopathy, muscle weakness.
Click to view Nimbex detailed prescribing information
Drug Interactions
Increased effect by anaesth agents eg, enflurane, isoflurane, halothane & ketamine; other non-depolarising neuromuscular blocking agents or by other drugs eg, antibiotics, antiarrhythmics, diuretics, Mg & lithium salts & ganglion blocking drugs. Various antibiotics, β-blockers, antiarrhythmics, antirheumatic drugs, trimetaphan, chlorpromazine, steroids, phenytoin & lithium may aggravate or unmask latent myasthenia gravis or induce a myasthenic syndrome. Decreased effect w/ chronic administration of phenytoin or carbamazepine. Treatment w/ anticholinesterase eg, donepezil may shorten duration & diminish the magnitude of neuromuscular blockade. Administration of suxamethonium to prolong the effects of non-depolarising neuromuscular blocking agents may result in a prolonged & complex block which can be difficult to reverse w/ anticholinesterases.
Click to view Nimbex detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Nimbex detailed prescribing information
Storage
View Nimbex storage conditions for details to ensure optimal shelf-life.
Description
View Nimbex description for details of the chemical structure and excipients (inactive components).
Action
View Nimbex mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Neuromuscular Blocking Agents
ATC Classification
M03AC11 - cisatracurium ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.
Presentation/Packing
Form
Nimbex inj 10 mg/5 mL
Packing/Price
5 × 1's
Form
Nimbex inj 5 mg/2.5 mL
Packing/Price
5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in